In a 12-week, double blind study, patients were randomized to receive Cymbalta 60 mg once (n=118) or twice daily (n=116), or placebo (n=120). The primary outcome measure was Brief Pain Inventory ...
The MarketWatch News Department was not involved in the creation of this content. May 09, 2022 (The Expresswire) -- The “Duloxetine Market” report delivers analysis of key important aspects ...